{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:55Z","timestamp":1792787275459,"version":"4.5.0"},"reference-count":34,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"unspecified","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"SCI Publication Grant Fund of West China Hospital of Sichuan University","award":["141110252"],"award-info":[{"award-number":["141110252"]}],"id":[{"id":"https:\/\/ror.org\/007mrxy13","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,1]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Extracorporeal circuit (EC) clotting remains a major challenge in continuous kidney replacement therapy (CKRT). While regional citrate anticoagulation (RCA) is recommended first-line, nafamostat mesylate (NM) offers an alternative with potential anti-inflammatory benefits. This trial aims to compare the effects of RCA, NM and their combination on EC lifespan during CKRT in critically ill acute kidney injury (AKI) patients with sepsis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a single-centre, prospective, three-arm, open-label, randomised controlled trial. Critically ill adult patients with AKI with sepsis requiring CKRT will be enrolled. Participants will be randomly assigned (1:1:1) to receive RCA, NM or combined RCA+NM anticoagulation. The primary outcome is EC lifespan. Secondary outcomes include EC survival rates, patient mortality, inflammatory biomarker levels and safety events (eg, bleeding, citrate accumulation). The sample size of 258 patients (86 per group) was calculated to detect a significant difference in the primary outcome with 90% power. Analysis will follow the intention-to-treat principle, using Kaplan-Meier survival analysis and Cox regression for the primary outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The RCNM-CKRT trial has been approved by the Biomedical Ethics Review Committee of West China Hospital, Sichuan University. We plan to present the results of our research at an international conference and publish in a peer-reviewed journal. The study data will be available on request, ensuring transparency and accessibility.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial registration number<\/jats:bold>\n                      :\n                    <\/jats:p>\n                    <jats:p>ChiCTR2600121436; Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-121232","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:48Z","timestamp":1790614848000},"page":"e121232","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Regional citrate anticoagulation combined with nafamostat mesylate for continuous kidney replacement therapy in septic acute kidney injury patients: protocol for a prospective, three-arm, randomised controlled study (RCNM-CKRT)"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1712-7031","authenticated-orcid":false,"given":"Qing","family":"Xu","sequence":"first","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Zou","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China"},{"name":"Department of Critical Care Medicine, Lhasa People\u2019s Hospital, Lhasa, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fu","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1155-4802","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Kidney Research Institute, Division of Nephrology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"2026092810002274000_16.9.e121232.1","doi-asserted-by":"crossref","unstructured":"Liu S-Y , Xu S-Y , Yin L , et al . Management of regional citrate anticoagulation for continuous renal replacement therapy: guideline recommendations from Chinese emergency medical doctor consensus. Mil Med Res 2023;10. doi:10.1186\/s40779-023-00457-9","DOI":"10.1186\/s40779-023-00457-9"},{"key":"2026092810002274000_16.9.e121232.2","doi-asserted-by":"crossref","first-page":"151473","DOI":"10.1016\/j.semnephrol.2023.151473","article-title":"Clotting of the extracorporeal circuit in hemodialysis: beyond contact-activated coagulation","volume":"43","author":"Engelen","year":"2023","journal-title":"Semin Nephrol"},{"key":"2026092810002274000_16.9.e121232.3","doi-asserted-by":"publisher","DOI":"10.1067\/mlc.2001.116486"},{"key":"2026092810002274000_16.9.e121232.4","doi-asserted-by":"crossref","unstructured":"Zhou Z , Liu C , Yang Y , et al . Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care 2023;27. doi:10.1186\/s13054-023-04519-1","DOI":"10.1186\/s13054-023-04519-1"},{"key":"2026092810002274000_16.9.e121232.5","doi-asserted-by":"crossref","unstructured":"Stucker F , Ponte B , Tataw J , et al . Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care 2015;19. doi:10.1186\/s13054-015-0822-z","DOI":"10.1186\/s13054-015-0822-z"},{"key":"2026092810002274000_16.9.e121232.6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01280214"},{"key":"2026092810002274000_16.9.e121232.7","doi-asserted-by":"crossref","unstructured":"Pistolesi V , Morabito S , Pota V , et al . Regional citrate anticoagulation (RCA) in critically ill patients undergoing renal replacement therapy (RRT): expert opinion from the SIAARTI-SIN joint commission. J Anesth Analg Crit Care 2023;3. doi:10.1186\/s44158-023-00091-w","DOI":"10.1186\/s44158-023-00091-w"},{"key":"2026092810002274000_16.9.e121232.8","doi-asserted-by":"crossref","unstructured":"Oudemans-van Straaten HM . Citrate for continuous renal replacement therapy: safer, better and cheaper. Crit Care 2014;18. doi:10.1186\/s13054-014-0661-3","DOI":"10.1186\/s13054-014-0661-3"},{"key":"2026092810002274000_16.9.e121232.9","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/aor.14276","article-title":"Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: a systematic review","volume":"46","author":"Sanfilippo","year":"2022","journal-title":"Artif Organs"},{"key":"2026092810002274000_16.9.e121232.10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2022.07.022","article-title":"Anticoagulation with nafamostat mesilate during extracorporeal life support","volume":"366","author":"Lang","year":"2022","journal-title":"Int J Cardiol"},{"key":"2026092810002274000_16.9.e121232.11","first-page":"164","article-title":"Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system","volume":"15","author":"Hitomi","year":"1985","journal-title":"Haemostasis"},{"key":"2026092810002274000_16.9.e121232.12","first-page":"767","article-title":"Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation","volume":"27","author":"Tsukagoshi","year":"2000","journal-title":"Gan To Kagaku Ryoho"},{"key":"2026092810002274000_16.9.e121232.13","doi-asserted-by":"crossref","unstructured":"Abe M , Shiga H , Tatsumi H , et al . Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes. Ren Replace Ther 2022;8. doi:10.1186\/s41100-022-00445-0","DOI":"10.1186\/s41100-022-00445-0"},{"key":"2026092810002274000_16.9.e121232.14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00011-023-01794-0","article-title":"Nafamostat mesilate prevented caerulein-induced pancreatic injury by targeting HDAC6-mediated NLRP3 inflammasome activation","volume":"72","author":"Chen","year":"2023","journal-title":"Inflamm Res"},{"key":"2026092810002274000_16.9.e121232.15","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.athoracsur.2004.09.005","article-title":"Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation","volume":"79","author":"Hiramatsu","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"2026092810002274000_16.9.e121232.16","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5414\/CP204852","article-title":"Effect of extracorporeal anticoagulation with nafamostat mesilate and continuous renal replacement therapy in sepsis complicated by acute kidney injury","volume":"64","author":"Zhang","year":"2026","journal-title":"CP"},{"key":"2026092810002274000_16.9.e121232.17","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2024.0419"},{"key":"2026092810002274000_16.9.e121232.18","doi-asserted-by":"crossref","unstructured":"Liu D , Zhao J , Xia H , et al . Nafamostat mesylate versus regional citrate anticoagulation for continuous renal replacement therapy in patients at high risk of bleeding: a retrospective single-center study. Eur J Med Res 2024;29. doi:10.1186\/s40001-024-01660-7","DOI":"10.1186\/s40001-024-01660-7"},{"key":"2026092810002274000_16.9.e121232.19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1177\/03913988251360552","article-title":"Different anticoagulation methods for continuous renal replacement therapy in patients with hyperlactataemia and a high risk of bleeding","volume":"48","author":"Song","year":"2025","journal-title":"Int J Artif Organs"},{"key":"2026092810002274000_16.9.e121232.20","doi-asserted-by":"crossref","unstructured":"Zeng X , Cai X , Liao Z , et al . Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety. Ren Fail 2025;47. doi:10.1080\/0886022X.2025.2580058","DOI":"10.1080\/0886022X.2025.2580058"},{"key":"2026092810002274000_16.9.e121232.21","doi-asserted-by":"crossref","unstructured":"Wang D , Yang M , Li S , et al . Efficacy and safety of low-molecular-weight-heparin plus citrate in nephrotic syndrome during continuous kidney replacement therapy: retrospective study. PeerJ 2025;13. doi:10.7717\/peerj.18919","DOI":"10.7717\/peerj.18919"},{"key":"2026092810002274000_16.9.e121232.22","doi-asserted-by":"crossref","unstructured":"Valle E de O , Cabrera CPS , Albuquerque C de , et al . Continuous renal replacement therapy in COVID-19-associated AKI: adding heparin to citrate to extend filter life-a retrospective cohort study. Crit Care 2021;25. doi:10.1186\/s13054-021-03729-9","DOI":"10.1186\/s13054-021-03729-9"},{"key":"2026092810002274000_16.9.e121232.23","doi-asserted-by":"crossref","unstructured":"Chan A-W , Boutron I , Hopewell S , et al . SPIRIT 2025 statement: updated guideline for protocols of randomised trials. BMJ 2025;389. doi:10.1136\/bmj-2024-081477","DOI":"10.1136\/bmj-2024-081477"},{"key":"2026092810002274000_16.9.e121232.24","doi-asserted-by":"publisher","DOI":"10.1159\/000339789"},{"key":"2026092810002274000_16.9.e121232.25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.0287"},{"key":"2026092810002274000_16.9.e121232.26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2215\/CJN.0000000000000351","article-title":"Regional citrate anticoagulation versus no anticoagulation for CKRT in patients with liver failure with increased bleeding risk","volume":"19","author":"Bai","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092810002274000_16.9.e121232.27","first-page":"S40","article-title":"Dose in continuous renal replacement therapy","volume":"154","author":"Claure-Del Granado","year":"2018","journal-title":"Gac Med Mex"},{"key":"2026092810002274000_16.9.e121232.28","doi-asserted-by":"publisher","DOI":"10.1186\/cc9415"},{"key":"2026092810002274000_16.9.e121232.29","doi-asserted-by":"crossref","unstructured":"Li P , Li M , Yin W , et al . Efficacy and safety of regional citrate anticoagulation using calcium-containing replacement solution in different modalities of continuous renal replacement therapy: a randomized controlled trial. BMC Nephrol 2025;26. doi:10.1186\/s12882-025-04565-7","DOI":"10.1186\/s12882-025-04565-7"},{"key":"2026092810002274000_16.9.e121232.30","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00048-8"},{"key":"2026092810002274000_16.9.e121232.31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jama.2020.18618","article-title":"Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically Ill patients with acute kidney injury: a randomized clinical trial","volume":"324","author":"Zarbock","year":"2020","journal-title":"JAMA"},{"key":"2026092810002274000_16.9.e121232.32","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/CCM.0000000000001004","article-title":"A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically Ill adults","volume":"43","author":"Gattas","year":"2015","journal-title":"Crit Care Med"},{"key":"2026092810002274000_16.9.e121232.33","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.02.349"},{"key":"2026092810002274000_16.9.e121232.34","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1007\/s00467-022-05502-8","article-title":"Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy","volume":"37","author":"Miyaji","year":"2022","journal-title":"Pediatr Nephrol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-121232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:54Z","timestamp":1790614854000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-121232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-121232"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-121232","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}